VIDEO: Sparsentan well-tolerated, demonstrated sustained anti-proteinuria effects
Click Here to Manage Email Alerts
Key takeaways:
- Absolute overall change in kidney function for patients treated with sparsentan was –5.8 mL/min/1.73 m2.
- Treatment effects on eGFR slope were consistent across baseline eGFR and proteinuria.
PHILADELPHIA — Sparsentan was shown to be well-tolerated and demonstrated sustained anti-proteinuria effects at the final analysis of 110 weeks, according to research presented at ASN Kidney Week.
Brad H. Rovin, chief of nephrology at The Ohio State University Wexner Medical Center, presented results of the phase 3 PROTECT Trial, here. Results showed that patients treated with sparsentan (Filspari, Travere Therapeutics) had an absolute overall change in kidney function from baseline to the end of the study of –5.8 mL/min/1.73 m2 compared with –9.5 mL/min/1.73 m2 with irbesartan, which translated into a 3.7 mL/min/1.73 m2 higher eGFR at 2 years with sparsentan compared with the comparator. Treatment effects on eGFR slope were also consistent across baseline eGFR and proteinuria, supporting the potential for sparsentan as a foundational treatment option across different stages of disease.
“In my practice and what I am looking at now is the goal ought to be the reduction of proteinuria as much as we can reduce it in patients with IgA to ensure kidney survival over a person’s lifetime,” Rovin said. “I think that we can think about sparsentan, which is not an immunosuppressive drug, as a foundational therapy for IgA nephropathy and then we can add other therapies, immunomodulators for example, on top of that to really try to treat this disease and keep patients away from needing kidney replacement therapy.”
References:
Rovin BH, et al. Lancet. 2023; doi:https://doi.org/10.1016/S0140-6736(23)02302-4.
Travere Therapeutics announces late-breaking data from phase 3 studies of sparsentan in IgAN and FSGS published in the Lancet and the NEJM respectively and presented at the American Society of Nephrology (ASN) Kidney Week 2023.
https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-late-breaking-data-phase-3. Published Nov. 3, 2023. Accessed Nov. 3, 2023.
Collapse
Read more about
Click Here to Manage Email Alerts